Key result
Propafenone was superior to disopyramide in reducing the median number of premature ventricular complexes (91.4% vs. 63.5%, p<0.01) and had fewer side effects.
Why the study?
Does propafenone improve PVC suppression compared to disopyramide in patients with symptomatic premature ventricular complexes?
Population
38 patients with symptomatic premature ventricular complexes (PVCs)
Comparison
Propafenone 150 mg four times daily vs Disopyramide 100 mg four times daily
Design
RCT, randomized cross-over, single-blind (ECG analyzed blindly)
Authors
Loading...
Supports preferring propafenone to disopyramide for symptomatic PVCs; strengthens RCT evidence for class Ic over class Ia agents.
RCT (n=38)
Single-blind
Randomized
Does propafenone improve PVC suppression compared to disopyramide in patients with symptomatic premature ventricular complexes?
Absolute Event Rate: 91.4% vs 63.5%
p-value: p=<0.01
Propafenone 150 mg four times daily is superior to disopyramide 100 mg four times daily in suppressing symptomatic PVCs and is associated with fewer side effects.
Jonason et al. (1988) conducted an RCT in Symptomatic premature ventricular complexes (PVCs) (n=38). Propafenone vs. Disopyramide, 100 mg four times daily was evaluated on Median reduction in the number of PVCs (p=<0.01). Propafenone was superior to disopyramide in reducing the median number of premature ventricular complexes (91.4% vs. 63.5%, p<0.01) and had fewer side effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: